Gender specific association of genetic variation in peroxisome proliferator-activated receptor (PPAR)γ-2 with longevity

Experimental Gerontology

Volumn 39, Issue 7, 2004, Pages 1095-1100

  Barbieri, Michelangela ^a   Bonafè, Massimiliano ^b   Rizzo, Maria Rosaria ^a   Ragno, Emilia ^a   Olivieri, Fabiola ^b   Marchegiani, Francesca ^b   Franceschi, Claudio ^b   Paolisso, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Ageing body composition; Human longevity; PPAR ; Pro12Ala gene polymorphism

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOSE TISSUE; ADULT; AGED; ALLELE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; INSULIN SENSITIVITY; LIPID METABOLISM; LONGEVITY; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SEX ROLE;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANTHROPOMETRY; BODY COMPOSITION; BODY MASS INDEX; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LONGEVITY; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SEX CHARACTERISTICS; TRANSCRIPTION FACTORS; VARIATION (GENETICS);

EID: 3242724126     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2004.03.034     Document Type: Article

References (52)

1. Alberti K.G.M.M., Zimmet P.Z., for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet. Med. 15:1998;539-553
2. Altshuler D., Hirschhorn J.N., Klannemark M., Lindgren C.M., Vohl M.C., Nemesh J., Lane C.R., Schaffner S.F., Bolk S., Brewer C., Tuomi T., Gaudet D., Hudson T.J., Daly M., Groop L., Lander E.S. The common PPAR Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26:2000;76-80
3. Altukhov Y.P., Sheremet'eva V.A. Genomic heterozygosity and human longevity. Dokl. Biol. Sci. 371:(1-6):2000;197-199
4. Beamer B.A., Negri C., Yen C.J., Gavrilova O., Rumberger J.M., Durcan M.J., Yarnall D.P., Hawkins A.L., Griffin C.A., Burns D.K., Roth J., Reitman M., Shuldiner A.R. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene. Biochem. Biophys. Res. Commun. 233:(3):1997;756-759
5. Beamer B.A., Yen C.J., Andersen R.E., Muller D., Elahi D., Cheskin L.J., Andres R., Roth J., Shuldiner A.R. Association of the Pro/Ala variant in the peroxisome proliferator activated receptor γ2 gene with obesity in two Caucasian population. Diabetes. 47:1998;1806-1808
6. Blanquart C., Barbier O., Fruchart J.C., Staels B., Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J. Steroid Biochem. Mol. Biol. 85:(2-5):2003;267-273
7. Bonafè M., Olivieri F., Cavallone L., Giovagnetti S., Marchegiani F., Cardelli M., Pieri C., Marra M., Antonicelli R., Rosmarie L., Rizzo M.R., Paolisso G., Monti D., Franceschi C. A gender dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur. J. Immunol. 31:2001;2357-2361
8. Bonafè M., Cardelli M., Marchegiani F., Cavallone L., Giovagnetti S., Olivieri F., Lisa R., Pieri C., Franceschi C. Increase of homozygosity in centenarians revealed by a new inter-Alu PCR technique. Exp. Gerontol. 36:(7):2001;1063-1073
9. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M.B., Monauni T., Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 23:2000;57-63
10. Caruso C., Candore G., Colonna, Romano G., Lio D., Bonafe M., Valensin S., Franceschi C. HLA, aging, and longevity: a critical reappraisal. Hum. Immunol. 61:(9):2000;942-949
11. Chen Y.J., Vortmeyer A., Zhuang Z., Huang S., Jensen R.T. Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance. Cancer Res. 15. 63:(4):2003;817-823
12. Clement K., Hercberg S., Passinge B., Galan P., Varroud-Vial M., Shuldiner A.R., Beamer B.A., Charpentier G., Guy-Grand B., Froguel P., Vaisse C. The Pro115Gln and Pro12Ala PPAR gene mutations in obesity and type 2 diabetes. Int. J. Obes. Relat. Metab. Disord. 24:2000;391-393
13. De Benedictis G., Rose G., carrieri G., De Luca M., Falcone E., Passarino G., Bonafè M., Monti D., Baggio G., Bertolini S., Mari D., Mattace R., Franceschi C. Mithocondrial DNA inherited variants are associated with succesful ageing and longevity in humans. FASEB J. 13:1999;1532-1536
14. Deeb S.S., Fajas L., Nemoto M., Pihlajamaki J., Mykkanen L., Kuusisto J., Laakso M., Fujimoto W., Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20:(3):1998;284-287
15. Ek J., Urhammer S.A., Sorensen T.I., Andersen T., Auwerx J., Pedersen O. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia. 42:(7):1999;892-895
16. Elbrecht A., Chen Y., Cullinan C.A., Hayes N., Leibowitz M., Moller D.E., Berger J. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem. Biophys. Res. Commun. 224:1996;431-437
17. Ellerhorst J.A., Hildebrand W.H., Cavett J.W., Fernandez-Vina M.A., Hodges S., Poindexter N., Fischer H., Grimm E.A. Heterozygosity or homozygosity for 2 HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated with cytokine therapy. J. Urol. 169:(6):2003;2084-2088
18. Evans D., Mann W.A., Heer J., Michel U., Wendt D., Kortner B., Wolf A., Beisiegel U. Variation in the gene for human peroxisome proliferator activated receptor (PPAR) does not play a major role in the development of morbid obesity. Int. J. Obes. Relat. Metab. Disord. 24:2000;647-651
19. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A.M., Saladin R., Najib J., Laville M., Fruchart J.C., Deeb S., Vidal-Puig A., Flier J., Briggs M.R., Staels B., Vidal H., Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 272:(30):1997;18779-18789
20. Franceschi C., Motta L., Valensin S., Rapisarda R., Franzone A., Berardelli M., Motta M., Monti D., Bonafè M., Ferrucci L., Deiana L., Pes G.M., Carru C., Desole M.S., Barbi C., Sartoni G., Gemelli C., Lescai F., Olivieri F., Marchegiani F., Cardelli M., Cavallone L., Gueresi P., Cossarizza A., Troiano L., Pini G., Sansoni P., Passeri G., Lisa R., Spazzafumo L., Amadio L., Giunta S., Stecconi R., Morresi R., Viticchi C., Mattace R., De Benedictis G., Baggio G. Do men and women follow different trajectories to reach extreme longevity? Aging Clin. Exp. Res. 12:2000;77-84
21. Gerkins V.R., Ting A., Menck H.T., Casagrande J.T., Terasaki P.I., Pike M.C., Henderson B.E. HLA heterozygosity as a genetic marker of long term survival. J. Natl Cancer Inst. 52:1974;109-111
22. Hasstedt S.J., Ren Q.-F., Teng K., Elbein S.C. Effect of the peroxisome proliferator-activated receptor-2 Pro12Ala variant on obesity, glucose homeostasis, and blood pressure in members of familial Type 2 diabetic kindreds. J. Clin. Endocrinol. Metab. 86:2001;536-541
23. Ho W.L., Chang J.W., Tseng R.C., Chen J.T., Chen C.Y., Jou Y.S., Wang Y.C. Loss of heterozygosity at loci of candidate tumor suppressor genes in microdissected primary non-small cell lung cancer. Cancer Detect. Prev. 26:(5):2002;343-349
24. Hsueh W.A., Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am. J. Cardiol. 18. 92:(4A):2003;3J-9J
25. Ivanova R., Henon N., Lepage V., Charron D., Vicaut E., Schachter F. HLA-DR alleles display sex-dependent effects on survival and discriminate between individual and familial longevity. Hum. Mol. Genet. 7:(2):1998;187-194
26. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health and diseases. Nature. 405:2000;421-424
27. Koch M., Rett K., Maerker E., Volk A., Haist K., Deninger M., Renn W., Haring H.U. The PPAR2 amino acid polymorphism Pro12Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia. 42:1999;758-762
28. Lemberger T., Braissant O., Juge-Aubry C., Keller H., Saladin R., Staels B., Auwerx J., Burger A.G., Meier C.A., Wahli W. PPAR tissue distribution and interactions with other hormone-signaling pathways. Ann. N. Y. Acad. Sci. 804:1996;231-251
29. Lemberger T., Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu. Rev. Cell Dev. Biol. 12:1996;335-363
30. Mancini F.P., Vaccaro O., Sabatino L., Tufano A., Rivellese A.A., Riccardi G., Colantuoni V. Pro12Ala substitution in the peroxisome proliferator-activated receptor γ 2 is not associated with type 2 diabetes. Diabetes. 48:1999;1466-1468
31. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:1985;412-419
32. Meirhaeghe A., Fajas L., Helbecque N., Cottel D. Impact of the peroxisome proliferator activated receptor 2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int. J. Obes. Relat. Metab. Disord. 24:2000;195-199
33. Olefsky J.M. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J. Clin. Invest. 106:(4):2000;467-472
34. Paolisso G., Gambardella A., Balbi V., Ammendola S., D'Amore A., Varricchio M. Body composition, body fat distribution and resting metabolic rate in healthy centenarians. Am. J. Clin. Nutr. 62:1995;746-750
35. Paolisso G., Barbieri M., Bonafe' M., Franceschi C. Metabolic age remodeling: the lessons from centenarians. Eur. J. Clin. Invest. 30:(10):2000;888-894
36. Penn D.J., Damjanovich K., Potts W.K. MHC heterozygosity confers a selective advantage against multiple-strain infections. Proc. Natl Acad. Sci. USA 20. 99:(17):2002;11260-11264
37. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol. 18. 92:(4A):2003;34J-41J
38. Puca A.A., Daly M.J., Brewster S.J., Matise T.C., Barrett J., Shea-Drinkwater M., Kang S., Joyce E., Nicoli J., Benson E., Kunkel L.M., Perls T. A genome-wide scan for linkage to human exceptional longevity identifies a locus on chromosome 4. Proc. Natl Acad. Sci. USA 28. 98:(18):2001;10505-10508
39. Ricote M., Li A.C., Wilson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor (PPARgamma) is a negative regulator of macrophage activation. Nature. 391:1998;79-82
40. Ricote M., Huang J.T., Welch J.S., Glass C.K. The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function. J. Leukoc. Biol. 66:(5):1999;733-739
41. Ristow M., Muller-Wieland D., Pfeiffer A., Krone W., Kahn C.R. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl. J. Med. 1. 339:(14):1998;953-959
42. Rosmond R., Chagnon M., Bouchard C. The Pro12Ala PPARgamma2 gene missense mutation is associated with obesity and insulin resistance in Swedish middle-aged men. Diabetes Metab. Res. Rev. 19:(2):2003;159-163
43. Rosmond R., Chagnon M., Bouchard C. The Pro12Ala PPARgamma2 gene missense mutation is associated with obesity and insulin resistance in Swedish middle-aged men. Diabetes Metab. Res. Rev. 19:(2):2003;159-163
44. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed.:1989;Cold Spring Harbor laboratory Press, Cold Spring Harbor, New York
45. Schachter F., Faure-Delanef L., Guenot F., Rouger H., Froguel P., Lesueur-Ginot L., Cohen D. Genetic associations with human longevity at the APOE and ACE loci. Nat. Genet. 6:(1):1994;29-32
46. Schneider J., Kreuzer J., Hamann A., Nawroth P.P., Dugi K.A. The proline 12 alanine substitution in the peroxisome proliferator-activated receptor-gamma2 gene is associated with lower lipoprotein lipase activity in vivo. Diabetes. 51:(3):2002;867-870
47. Spiegelman B.M. PPARg: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:1998;507-514
48. Thatcher A.R., Kannisto V., Vaupel J.W. The Forces of Mortality at Age 80 to 120. Odense Monographs on Population Aging. vol. 5:1998;Odence University Press
49. Valve R., Sivenius K., Miettinen R., Pihlajamaki J., Rissanen A., Deeb S.S., Auwerx J., Uusitupa M., Laakso M. Two polymorphisms in the peroxisome proliferator-activated receptor-gene are associated with severe overweight among obese women. J. Clin. Endocrinol. Metab. 84:1999;3708-3712
50. Yashin A.I., De Benedictis G., Vaupel J.W., Tan Q., Andreev K.F., Iachine I.A., Bonafè M., De Luca M., Valensin S., Carotenuto L., Franceschi C. Genes, demography and life span: the contribution of demographic data and genetic studies on ageing and longevity. Am. J. Hum. Genet. 65:(4):1999;1178- 1193
51. Yen C.J., Beamer B.A., Negri C., Silver K., Brown K.A., Yarnall D.P., Burns D.K., Roth J., Shuldiner A.R. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem. Biophys. Res. Commun. 241:(2):1997;270-274
52. Zietz B., Barth N., Spiegel D., Schmitz G., Scholmerich J., Schaffler A. A Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 (PPARgamma2) is associated with higher levels of total cholesterol and LDL-cholesterol in male caucasian type 2 diabetes patients. Exp. Clin. Endocrinol. Diabetes. 110:(2):2002;60-66